Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06716138 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 6 to 5v4
  2. Study sites: 5 to 6 Start date: Feb 10, 2025 to Mar 6, 2025v3 Show 1 more changeShow less
    • Start date: Feb 10, 2025 to Mar 6, 2025
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 4 to 5 · Start date changed from estimate of Mar 1, 2025 to Feb 10, 2025v2 Show 2 more changesShow less
    • Study sites: 4 to 5
    • Start date changed from estimate of Mar 1, 2025 to Feb 10, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Trial Details
NCT Number NCT06716138
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov